Delfi Diagnostics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 54)
Delfi Diagnostics logo

Delfi Diagnostics

ChallengerLife Sciences & BioTech

Liquid Biopsy & Early Cancer Detection

Delfi Diagnostics has raised $332M total to develop blood-based cancer detection using whole-genome cfDNA fragmentation analysis and ML; clinically validated FirstLook Lung test; partnering with Hackensack Meridian Health in 2025;

AI VisibilityBeta
Overall Score
C54
Category Rank
#25 of 198
AI Consensus
89%
Trend
stable
Per Platform
ChatGPT
55
Perplexity
59
Gemini
58

About

Delfi Diagnostics is a biotechnology company founded in 2019 by Victor Velculescu and headquartered in Baltimore, Maryland, specializing in blood-based cancer detection using machine learning and whole-genome sequencing of cell-free DNA (cfDNA). The company''s AI platform analyzes genome-wide fragmentation patterns of cell-free DNA from a simple blood draw — a liquid biopsy — to detect cancer-associated signals across multiple cancer types. This approach, called DELFI (DNA Evaluation of Fragments for Early Interception), generates a large number of features across the entire genome that machine learning models synthesize into a cancer risk score.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

54
Overall Score
74
#25
Category Rank
#11
89
AI Consensus
68
stable
Trend
stable
55
ChatGPT
71
59
Perplexity
68
58
Gemini
80
59
Claude
77
59
Grok
69

Key Details

Category
Liquid Biopsy & Early Cancer Detection
AI-Enabled Precision Medicine
Tier
Challenger
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.